54 completed, 19 terminated, 16 active not recruiting, 12 recruiting. 69 Phase 2, 45 Phase 1, 10 Phase 3, 2 Early Phase 1, 1 Not applicable.
Follow cobimetinib: new trials by email Literature Review of cobimetinib trials Research Report on cobimetinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma Belvarafenib, Cobimetinib - Advanced or Metastatic Melanoma | Phase 2 | Recruiting | Hanmi Pharmaceutical Company Limited | 45 | 2026-02-12 | 2026-03-04 |
| Using Tumor Models to Determine Treatments Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer | Phase 2 | Recruiting | University Health Network, Toronto | 25 | 2025-04-07 | 2026-06-23 |
| Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation Biospecimen Collection, Cobimetinib, Computed Tomography - Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 21 | 2024-07-15 | 2026-02-02 |
| T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma T3011 + Cobimetinib - Melanoma, Malignant Melanoma | Phase 2 | Suspended | ImmVira Pharma Co. Ltd | 68 | 2024-06-30 | 2024-02-01 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Cobimetinib, Enasidenib Mesylate - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Completed | City of Hope Medical Center | 3 | 2023-04-28 | 2026-05-05 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer Biopsy, Calaspargase Pegol-mknl, Cobimetinib - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Completed | OHSU Knight Cancer Institute | 15 | 2022-08-09 | 2026-07-23 |
| Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study) Cobimetinib - Arteriovenous Malformations (Extracranial) | Phase 2 | Completed | University of Arkansas | 3 | 2022-07-26 | 2026-11-12 |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US Encorafenib, Binimetinib, Vemurafenib - Melanoma | Completed | Pfizer | 716 | 2022-01-17 | 2025-03-06 | |
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 57 | 2021-12-15 | 2025-05-23 |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2026-11-10 |
| CRAFT: The NCT-PMO-1602 Phase II Trial Vemurafenib, Cobimetinib, Atezolizumab - Metastatic or Locally Advanced Malignancies | Phase 2 | Completed | German Cancer Research Center | 72 | 2021-10-13 | 2025-01-08 |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors Ipatasertib, Cobimetinib, Trastuzumab Emtansine - Ovarian Cancer | Phase 2 | Active not recruiting | Hoffmann-La Roche | 176 | 2021-10-07 | 2026-09-10 |
| Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study Trametinib, Cobimetinib, Binimetinib - Cancer | Not applicable | Terminated | Peter MacCallum Cancer Centre, Australia | 3 | 2021-09-23 | 2023-05-10 |
| A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. Belvarafenib, Cobimetinib, Nivolumab - Melanoma | Phase 1 | Active not recruiting | Genentech, Inc. | 65 | 2021-05-13 | 2026-09-30 |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders Cobimetinib - Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma | Phase 2 | Recruiting | Carl Allen | 90 | 2021-04-19 | 2026-10-26 |
| Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations Cobimetinib - Chronic Myelomonocytic Leukemia (CMML) | Phase 2 | Active not recruiting | University of Utah | 14 | 2021-01-12 | 2026-10-26 |
Showing 20 of 112. Sign in to see all of them.
Melanoma (34) · Neoplasms (14) · Carcinoma, Non-Small-Cell Lung (10) · Colorectal Neoplasms (8) · Ovarian Neoplasms (7) · Breast Neoplasms (6) · Multiple Myeloma (6) · Pancreatic Neoplasms (5) · Hematologic Neoplasms (4) · Neoplasm Metastasis (4) · Brain Neoplasms (3) · Cholangiocarcinoma (3) · Gastrointestinal Neoplasms (3) · Leukemia, Myeloid, Acute (3) · Lung Neoplasms (3)
Hoffmann-La Roche (26) · Genentech, Inc. (16) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · OHSU Knight Cancer Institute (4) · Fondazione Melanoma Onlus (3) · Bristol-Myers Squibb (2) · Cancer Research UK (2) · City of Hope Medical Center (2) · Hanmi Pharmaceutical Company Limited (2) · Peter MacCallum Cancer Centre, Australia (2) · ABM Therapeutics Corporation (1) · Alliance for Clinical Trials in Oncology (1) · American Society of Clinical Oncology (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (74) · Spain (24) · France (21) · Germany (20) · Italy (20) · Australia (19) · South Korea (18) · United Kingdom (16) · Canada (13) · Belgium (11) · Netherlands (9) · Poland (9) · Brazil (8) · Israel (8) · Russia (8)
Isabelle Rooney, M.D., PhD (3) · Charles D Lopez (2) · Matthew Krebs, Dr (2) · Michael B Atkins, MD (2) · Mohammed Milhem, MD (2) · Nilofer S Azad (2) · Alfonso Berrocal, MD, PhD (1) · Ami Patel, MD (1) · Andrea Botticelli (1) · Anna Pavlick, MD (1) · Brian Ball (1) · Carl E Allen, MD, PhD (1) · Claus Garbe, Prof. (1)
PMID 36310331, PMID 33476492, PMID 32746839, PMID 36648215, PMID 36940261, PMID 22651703, PMID 24577748, PMID 25037139, PMID 25265494, PMID 27269741, PMID 27480103, PMID 27733243, PMID 28444112, PMID 28592615, PMID 28646893, PMID 28734759, PMID 28915798, PMID 29320312, PMID 29355075, PMID 29489427, PMID 30110194, PMID 30857956, PMID 30918950, PMID 31003911, PMID 31100038, PMID 31171876, PMID 32086697, PMID 32534646, PMID 32737717, PMID 33068284, PMID 33090333, PMID 33407577, PMID 33720068, PMID 33844595, PMID 34158360, PMID 34339623, PMID 34637336, PMID 34808524, PMID 34825282, PMID 34853302, PMID 34876409, PMID 34907910, PMID 35086719, PMID 35131452, PMID 35587446, PMID 35598186, PMID 35649212, PMID 35715627, PMID 35940183, PMID 35995953
2016 (8), 2017 (6), 2014 (5), 2015 (3), 2018 (3), UM1CA186691 (3), P30CA033572 (2), 2023 (1), U10CA180821 (1), UM1CA186709 (1)